08.01.2024 - BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company ), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced .
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a report released on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock. A number of other analysts have also recently weighed in on the stock. Roth Mkm raised their price target on shares of Cyclacel Pharmaceuticals from $16.00 […]